Analytics of Cerebrospinal Fluid MicroRNA Quantitative PCR Studies.


Journal

Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 14 08 2018
accepted: 02 11 2018
pubmed: 16 11 2018
medline: 15 1 2020
entrez: 16 11 2018
Statut: ppublish

Résumé

MicroRNAs (miRNAs) are small non-coding RNAs that regulate post-transcriptional gene expression. Recent studies have shown that human disease states correlate with measurable differences in the level of circulating miRNAs relative to healthy controls. Thus, there is great interest in developing clinical miRNA assays as diagnostic or prognostic biomarkers for diseases, and as surrogate measures for therapeutic outcomes. Our studies have focused on miRNAs in human cerebral spinal fluid (CSF) as biomarkers for central nervous system (CNS) diseases. Our objective here was to examine factors that may affect the outcome of quantitative PCR (qPCR) studies on CSF miRNAs, in order to guide planning and interpretation of future CSF miRNA TaqMan® low-density array (TLDA) studies. We obtained CSF from neurologically normal (control) donors and used TLDAs to measure miRNA expression. We examined sources of error in the TLDA outcomes due to (1) nonspecific amplification of products in total RNA, (2) variations in RNA isolations performed on different days, (3) miRNA primer probe efficiency, and (4) variations in individual TLDA cards. We also examined the utility of card-to-card TLDA corrections and use of an unchanged "reference standard" to remove batch processing effects in large-scale studies.

Identifiants

pubmed: 30430409
doi: 10.1007/s12035-018-1422-0
pii: 10.1007/s12035-018-1422-0
pmc: PMC6527498
mid: NIHMS1524646
doi:

Substances chimiques

Biomarkers 0
MicroRNAs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4988-4999

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR000128
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002369
Pays : United States
Organisme : NIA NIH HHS
ID : P30AG008017
Pays : United States
Organisme : NCATS NIH HHS
ID : UH2 TR000903
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG008017
Pays : United States
Organisme : NCATS NIH HHS
ID : Oregon Clinical & Translational Research Institute UL1TR000128
Pays : United States
Organisme : NCATS NIH HHS
ID : UH3 TR000903
Pays : United States
Organisme : NCATS NIH HHS
ID : UH2/UH3TR000903
Pays : United States

Références

Stedman TL (2004) The American Heritage Stedman's medical dictionary. Houghton Mifflin Co., Boston
Quinn JF, Patel T, Wong D, Das S, Freedman JE, Laurent LC, Carter BS, Hochberg F et al (2015) Extracellular RNAs: development as biomarkers of human disease. J Extracell Vesicles 4:27495. https://doi.org/10.3402/jev.v4.27495
doi: 10.3402/jev.v4.27495 pubmed: 26320940
Rao P, Benito E, Fischer A (2013) MicroRNAs as biomarkers for CNS disease. Front Mol Neurosci 6:39. https://doi.org/10.3389/fnmol.2013.00039
doi: 10.3389/fnmol.2013.00039 pubmed: 24324397 pmcid: 3840814
Denk J, Boelmans K, Siegismund C, Lassner D, Arlt S, Jahn H (2015) MicroRNA profiling of CSF reveals potential biomarkers to detect Alzheimer’s disease. PLoS One 10:e0126423. https://doi.org/10.1371/journal.pone.0126423
doi: 10.1371/journal.pone.0126423 pubmed: 25992776 pmcid: 4439119
Gui Y, Liu H, Zhang L, Lv W, Hu X (2015) Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget 6:37043–37053. https://doi.org/10.18632/oncotarget.6158
doi: 10.18632/oncotarget.6158 pubmed: 26497684 pmcid: 4741914
Muller M, Jakel L, Bruinsma IB, Claassen JA, Kuiperij HB, Verbeek MM (2016) MicroRNA-29a is a candidate biomarker for Alzheimer's disease in cell-free cerebrospinal fluid. Mol Neurobiol 53:2894–2899. https://doi.org/10.1007/s12035-015-9156-8
doi: 10.1007/s12035-015-9156-8 pubmed: 25895659
van Harten AC, Mulders J, Scheltens P, van der Flier WM, Oudejans CB (2015) Differential expression of microRNA in cerebrospinal fluid as a potential novel biomarker for Alzheimer's disease. J Alzheimers Dis 47:243–252. https://doi.org/10.3233/JAD-140075
doi: 10.3233/JAD-140075 pubmed: 26402772
Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, Kim RY, Saria MG et al (2012) MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro-Oncology 14:689–700. https://doi.org/10.1093/neuonc/nos074
doi: 10.1093/neuonc/nos074 pubmed: 22492962 pmcid: 3367845
Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zollner H, Schmiegel W, Hahn S, Schroers R (2012) Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro-Oncology 14:29–33. https://doi.org/10.1093/neuonc/nor169
doi: 10.1093/neuonc/nor169 pubmed: 21937590
Wan Y, Liu Y, Wang X, Wu J, Liu K, Zhou J, Liu L, Zhang C (2015) Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder. PLoS One 10:e0121975. https://doi.org/10.1371/journal.pone.0121975
doi: 10.1371/journal.pone.0121975 pubmed: 25763923 pmcid: 4357380
Lusardi TA, Phillips JI, Wiedrick JT, Harrington CA, Lind B, Lapidus JA, Quinn JF, Saugstad JA (2017) MicroRNAs in human cerebrospinal fluid as biomarkers for Alzheimer's disease. J Alzheimers Dis 55:1223–1233. https://doi.org/10.3233/JAD-160835
doi: 10.3233/JAD-160835 pubmed: 27814298 pmcid: 5587208
Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J et al (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69:570–580. https://doi.org/10.1002/ana.22311
doi: 10.1002/ana.22311 pubmed: 21400565 pmcid: 3117674
Burgos K, Malenica I, Metpally R, Courtright A, Rakela B, Beach T, Shill H, Adler C et al (2014) Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology. PLoS One 9:e94839. https://doi.org/10.1371/journal.pone.0094839
doi: 10.1371/journal.pone.0094839 pubmed: 24797360 pmcid: 4010405
Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T et al (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55:611–622. https://doi.org/10.1373/clinchem.2008.112797
doi: 10.1373/clinchem.2008.112797
Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Hadfield J, Bertone P, Caldas C (2010) Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 16:991–1006. https://doi.org/10.1261/rna.1947110
doi: 10.1261/rna.1947110 pubmed: 20360395 pmcid: 2856892
Benes V, Castoldi M (2010) Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods 50:244–249. https://doi.org/10.1016/j.ymeth.2010.01.026
doi: 10.1016/j.ymeth.2010.01.026 pubmed: 20109550
Podlesniy P, Figueiro-Silva J, Llado A, Antonell A, Sanchez-Valle R, Alcolea D, Lleo A, Molinuevo JL et al (2013) Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Ann Neurol 74:655–668. https://doi.org/10.1002/ana.23955
doi: 10.1002/ana.23955 pubmed: 23794434
Pyle A, Brennan R, Kurzawa-Akanbi M, Yarnall A, Thouin A, Mollenhauer B, Burn D, Chinnery PF et al (2015) Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's disease. Ann Neurol 78:1000–1004. https://doi.org/10.1002/ana.24515
doi: 10.1002/ana.24515 pubmed: 26343811 pmcid: 6551217
Varhaug KN, Vedeler CA, Myhr KM, Aarseth JH, Tzoulis C, Bindoff LA (2017) Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis. Mitochondrion 34:32–35. https://doi.org/10.1016/j.mito.2016.12.003
doi: 10.1016/j.mito.2016.12.003 pubmed: 28017684
Saugstad JA, Lusardi TA, Van Keuren-Jensen KR, Phillips JI, Lind B, Harrington CA, McFarland TJ, Courtright AL et al (2017) Analysis of extracellular RNA in cerebrospinal fluid. J Extracell Vesicles 6:1317577. https://doi.org/10.1080/20013078.2017.1317577
doi: 10.1080/20013078.2017.1317577 pubmed: 28717417 pmcid: 5505019
Wang WX, Fardo DW, Jicha GA, Nelson PT (2017) A customized quantitative PCR MicroRNA panel provides a technically robust context for studying neurodegenerative disease biomarkers and indicates a high correlation between cerebrospinal fluid and choroid plexus MicroRNA expression. Mol Neurobiol 54:8191–8202. https://doi.org/10.1007/s12035-016-0316-2
doi: 10.1007/s12035-016-0316-2 pubmed: 27900678
Wolfinger RD, Beedanagari S, Boitier E, Chen T, Couttet P, Ellinger-Ziegelbauer H, Guillemain G, Mariet C et al (2018) Two approaches for estimating the lower limit of quantitation (LLOQ) of microRNA levels assayed as exploratory biomarkers by RT-qPCR. BMC Biotechnol 18:6. https://doi.org/10.1186/s12896-018-0415-4
doi: 10.1186/s12896-018-0415-4 pubmed: 29391006 pmcid: 5796571
Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, Vandesompele J (2009) A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10:R64. https://doi.org/10.1186/gb-2009-10-6-r64
doi: 10.1186/gb-2009-10-6-r64 pubmed: 19531210 pmcid: 2718498
Wylie D, Shelton J, Choudhary A, Adai AT (2011) A novel mean-centering method for normalizing microRNA expression from high-throughput RT-qPCR data. BMC Res Notes 4:555. https://doi.org/10.1186/1756-0500-4-555
doi: 10.1186/1756-0500-4-555 pubmed: 22188771 pmcid: 3267743
Brunet-Vega A, Quilez ME, Ramirez-Lazaro MJ, Lario S (2018) Application of individual qPCR performance parameters for quality control of circulating MicroRNA data. Methods Mol Biol 1699:187–199. https://doi.org/10.1007/978-1-4939-7435-1_14
doi: 10.1007/978-1-4939-7435-1_14 pubmed: 29086378
Gevaert AB, Witvrouwen I, Vrints CJ, Heidbuchel H, Van Craenenbroeck EM, Van Laere SJ, Van Craenenbroeck AH (2018) MicroRNA profiling in plasma samples using qPCR arrays: Recommendations for correct analysis and interpretation. PLoS One 13:e0193173. https://doi.org/10.1371/journal.pone.0193173
doi: 10.1371/journal.pone.0193173 pubmed: 29474497 pmcid: 5825041

Auteurs

Theresa A Lusardi (TA)

Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

Jack T Wiedrick (JT)

Biostatistics & Design Program, Oregon Health & Science University, Portland, OR, USA.

Molly Malone (M)

Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, OR, USA.

Jay I Phillips (JI)

Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, OR, USA.

Ursula S Sandau (US)

Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, OR, USA.

Babett Lind (B)

Department of Neurology, Layton Aging and Alzheimer's Center, Oregon Health & Science University, Portland, OR, USA.

Joseph F Quinn (JF)

Department of Neurology, Layton Aging and Alzheimer's Center, Oregon Health & Science University, Portland, OR, USA.
Portland VA Medical Center, Portland, OR, USA.

Jodi A Lapidus (JA)

Biostatistics & Design Program, Oregon Health & Science University, Portland, OR, USA.

Julie A Saugstad (JA)

Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, OR, USA. saugstad@ohsu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH